© < o 2 < =z < ° =o <,s= 2 esu= == qs ul ce ~= Lis < Lad “” 32 — 5 < 2a sZzSof ow efon" a2zosa ° ~” a , nea =) wa ja . <t 4 belies! a_i mem FO Li. _ a he a = wa sz =< == 1.3 Cow 1 I.V. citrate (acute) 72 1.3 a Cow 4 I.V. citrate (acute) 120 1.5 2 Cow 4 oral citrate 720 2.0 x 107% Cow 4 oral dioxide 624 2.0 x 1075 << 'e0 Le Eo ze] ta ==2 os o = re = ce Fr Sa uw <2 = = 2 a! a s = =o ] _t a 128 oe “ —_ © I.V. citrate (multiple) co oz = _ 2 ° = “a <t =5 = vt < . 2 vy 2 (acute) (acute) (multiple) 9 8< = had S © = = Figure 1 ~ Outline of some potential transport and recycling pathways for transuranic elements in food products, These pathways, some of which currently represent a very minor contribution, could become more important when long range hazard predictions are formulated. 442 of Dose Transported to Milk Goat zo == Duration of Collection(h) 1.0 26 zu Type of Dose 432 we ui Fe Number of Animals citrate ze o | Animal I.V. ai 25 Zo Total % 1 > >| =| TABLE IV BRIEF COMPARISON OF SELECTED STUDIES SHOWING THE PERCENTAGE OF EITHER INTRAVENOUS OR ORAL PLUTONIUM-238 DOSES TRANSFERRED TO MILK IN DAIRY ANIMALS Goat = “ a as 2 az 2o < 38; he - = <3 2< w Bn = — 3 <. _ ww bad ot CONCENTRATE FOR ANIMAL FEED . 4 E Some experiments on the transport of plutonium in dairy products have already been conducted by this Laboratory. While it has been noted that transfer of plutonium to milk ia relatively small, the subsequent production of cheese concentrated the available plutonium (Miller et ai., 1972). In further work, the biological availability of plutonium from milk labeled in vivo was investigated, Juvenile goats and calves were given multiple oral doses of either tn vivo plutonium labeled milk collected from intravenously dosed lactating adults, or in vitro plutonium labeled milk adjusted to the same plutonium concentration as the in vivo labeled milk. Analyses have not been completed on the calf tissues, but in the preliminary study using goats, no clearly discernible differences in plutonium retention were noted between the two treatment groups. 443